Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples